Anne-Marie Meyer

Anne-Marie Meyer

Auto-generated profile, based on publicly available information

Anne-Marie Meyer

Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2021 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
PDF file
LPLynne T. Penberthy
Lynne T. Penberthy
DRDonna R. Rivera
Donna R. Rivera
JLJennifer L. Lund
Jennifer L. Lund
MBMelissa A. Bruno
Melissa A. Bruno
AMAnne‐Marie Meyer
Anne‐Marie Meyer
Generating evidence on the use, effectiveness, and safety of new cancer therapies is a priority for researchers, health care providers, payers, and regulators given the rapid pace of change in cancer diagnosis and treatments. The use of real‐world data (RWD) is integral to understanding the utilization patterns and outcomes of these new treatments among patients with cancer who are treated in clinical practice and community settings. An initial step in the use of RWD is careful study design to assess the suitability of an RWD source. This pivotal process can be guided by using a conceptual model that encourages predesign conceptualization. The primary types of RWD included are electronic health records, administrative claims data, cancer registries, and specialty data providers and networks. Careful consideration of each data type is necessary because they are collected for a specific purpose, capturing a set of data elements within a certain population for that purpose, and they vary by population coverage and longitudinality. In this review, the authors provide a high‐level assessment of the strengths and limitations of each data category to inform data source selection appropriate to the study question. Overall, the development and accessibility of RWD sources for cancer research are rapidly increasing, and the use of these data requires careful consideration of composition and utility to assess important questions in understanding the use and effectiveness of new therapies.

20 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
SMSarah F. McGough
Sarah F. McGough
RGRyan W. Gan
Ryan W. Gan
RTRobert Tibshirani
Robert Tibshirani
AMAnne-Marie Meyer
Anne-Marie Meyer
The United States has become an epicenter for the coronavirus disease 2019 (COVID-19) pandemic. However, communities have been unequally affected and evidence is growing that social determinants of health may be exacerbating the pandemic. Furthermore, the impact and timing of social distancing at the community level have yet to be fully explored. We investigated the relative associations between COVID-19 mortality and social distancing, sociodemographic makeup, economic vulnerabilities, and comorbidities in 24 counties surrounding 7 major metropolitan areas in the US using a flexible and robust time series modeling approach. We found that counties with poorer health and less wealth were associated with higher daily mortality rates compared to counties with fewer economic vulnerabilities and fewer pre-existing health conditions. Declines in mobility were associated with up to 15% lower mortality rates relative to pre-social distancing levels of mobility, but effects were lagged between 25-30 days. While we cannot estimate causal impact, this study provides insight into the association of social distancing on community mortality while accounting for key community factors. For full transparency and reproducibility, we provide all data and code used in this study. One-sentence summary: County-level disparities in COVID19 mortality highlight inequalities in socioeconomic and community factors and delayed effects of social distancing.

23 September 2026
Verified
Other
Open access
JHJennifer N. Hoppe
Jennifer N. Hoppe
JLJocelyn Lee
Jocelyn Lee
TATomi Akinyemiju
Tomi Akinyemiju
DBDanielle S. Bitterman
Danielle S. Bitterman
MBMichael Brudno
Michael Brudno
JWJeremy L. Warner
Jeremy L. Warner
Detailed information on clinical domains

23 September 2026
Verified
Other
Open access
JHJennifer N. Hoppe
Jennifer N. Hoppe
JLJocelyn Lee
Jocelyn Lee
TATomi Akinyemiju
Tomi Akinyemiju
DBDanielle S. Bitterman
Danielle S. Bitterman
MBMichael Brudno
Michael Brudno
JWJeremy L. Warner
Jeremy L. Warner
Detailed information on GDM Logical Model

1 October 2026 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
AMAnne-Marie Meyer
Anne-Marie Meyer
SSShannon Silkensen
Shannon Silkensen
ETElizabeth Turi
Elizabeth Turi
MEMatthew Elrod
Matthew Elrod
WGWilliam Gordon
William Gordon
UTUmit Topaloglu
Umit Topaloglu

1 September 2026 in Cancer Research Communications
Verified
Journal Article
Open access
JHJennifer N. Hoppe
Jennifer N. Hoppe
JLJocelyn Lee
Jocelyn Lee
TATomi Akinyemiju
Tomi Akinyemiju
DBDanielle S. Bitterman
Danielle S. Bitterman
MBMichael Brudno
Michael Brudno
JWJeremy L. Warner
Jeremy L. Warner
Adequately powered analyses in precision oncology often require combining cohorts across institutions. However, integration is constrained by the least granular source and may become infeasible when data elements are too heterogeneous to harmonize and map to a common data model. This challenge is acute in multi-institutional precision oncology research, in which real-world evidence requires harmonized clinico-omic data integration. Existing models often lack sufficient treatment patterns, outcomes, and genomic data, limiting interoperability and scalability. To address these gaps, American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (GENIE) developed the GENIE Data Model (GDM), a comprehensive, open-source oncology data model for scalable, consistent, and interoperable data collection across solid tumors, designed to effectively capture the journey of patients with cancer. Through iterative consensus-building, four working groups comprising 13 subject matter experts defined data elements across multiple clinical domains: patient characteristics, imaging, diagnosis, surgery, histopathology, biomarkers, systemic therapy, radiation, clinical trial history, disease response and outcomes, and social determinants of health. Elements were defined using standardized terminologies and permissible values to support mapping to Health Level 7 Fast Healthcare Interoperability Resources, Observational Medical Outcomes Partnership, and other existing oncology standards. The model architecture distinguishes manually abstracted elements from computationally collected elements, enabling parallel workflows. The GDM provides an extensible framework that addresses critical gaps and enables scalable, harmonized data collection essential for precision oncology and real-world evidence generation. Significance: The GDM is an open-source, ready-to-implement, solid tumor framework that standardizes clinical and genomic data capture across institutions to effectively capture the journey of patients with cancer. It enables interoperable mapping to existing standards, accelerates multisite study start-up, and supports scalable real-world evidence generation in precision oncology.